Treats clinically important hypotension occurring in the setting of anesthesia. ANDA 218211, held by Gland. Ephedrine Sulfate.
As of Nov 16, 2026, ANDA 218211 (Ephedrine Sulfate), held by Gland, was first approved by FDA on Jan 16, 2025, with 0 approved supplements and 0 published complete response letters.
Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 16, 2025 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ephedrine Sulfate50MG/10ML (5MG/ML) · solution;intravenous | Ephedrine Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters